Unidentified Investor's questions to Scinai Immunotherapeutics Ltd (SCNI) leadership • Q2 2024
Question
An unidentified investor asked about Scinai's long-term strategy and the specific role the CDMO business unit plays within that plan.
Answer
CEO Amir Reichman outlined a phased strategy. In the near term, Scinai will develop its licensed technologies through Phase II and then partner with large pharma for late-stage development and commercialization, generating revenue via milestones and royalties. The CDMO unit is crucial to this plan, as it provides non-dilutive cash flow by serving the niche market of early-stage biotechs. This revenue offsets R&D costs, reduces shareholder risk, and provides valuable in-house experience that accelerates Scinai's own drug development programs.